Boston Scientific Corporation — Company profile
Healthcare · Medical Devices · United States
Last price 41.98 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 60.84B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Details
| Name | Boston Scientific Corporation |
| Sector | Healthcare |
| Industry | Medical Devices |
| Employees | 59000 |
| Founded | 1979 |
| Ipo Date | 1992-05-18 |
| Ceo | Michael Mahoney |
| Country | United States |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US1011371077 |
| Cusip | 101137107 |
| Cik | 0000885725 |
| Sic | 3841 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Michael F. Mahoney | Chairman, President and Chief Executive Officer |
| Jonathan R. Monson | Executive Vice President and Chief Financial Officer |
| Vance R. Brown J.D. | EVice President, General Counsel and Corporate Secretary |
| Joseph M. Fitzgerald | Executive Vice President and Group President of Cardiovascular |
| Arthur Crosswell Butcher | Executive Vice President and Group President of MedSurg and Asia Pacific |
| Paudie O'Connor | Executive Vice President of Global Operations |
| Emily M. Woodworth | Senior Vice President, Global Controller and Chief Accounting Officer |
| Adam Smith | General Manager of Global Sales and Marketing |
| Miriam O'sullivan | Senior Vice President and Chief Human Resources Officer |
| Brenda Becker | Senior Vice President of Global Government Affairs |
Contact
| Address | 300 Boston Scientific Way, Marlborough, Massachusetts 01752-1234, United States |
| Phone | 508 683 4000 |
| Website | https://www.bostonscientific.com |